BioSpace News Archive

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2024 and provided corporate updates.

VolitionRx Limited, a multi-national epigenetics company, announced financial results and a business update for the first quarter of 2024.

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the first quarter ended March 31, 2024.

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference on Monday, May 20, 2024, at 3:00 p.m. ET.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced financial results for the first quarter ended March 31, 2024, and provided an overview of recent operational highlights.

STRATA Skin Sciences, Inc. announces that Dr. Dolev Rafaeli, President and Chief Executive Officer, and Christopher Lesovitz, Chief Financial Officer, will participate in the Benchmark Healthcare House Call Virtual 1x1 Investor Conference being held on May 21 – 22, 2024.

Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset NPM-115 for chronic weight management in obese or overweight patients with one or more risk factors, today reported financial results for the first quarter ended March 31, 2024, and provided a business update.

Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer and autoimmune disease, announced the pricing of an underwritten offering of 37,931,035 shares of its common stock at a price of $2.90 per share.

The asthma and COPD drugs market size was valued at a USD 37.22 billion in 2022 and it is anticipated to reach USD 61.54 billion by 2032, with an expanding 5.01% of CAGR from 2023 to 2032.

According to the recent study by Astute Analytica, the U.S. liquid biopsy market is witnessing a rise a revenue from US$ 3,786.2 million in 2023 to surpass a market valuation of US$ 12,004.9 million by 2032.